Repros Therapeutics Inc. Release: Reanalysis by Outside Statistician Shows Androxal(R) Provides Statistically Significant Improvement in Testosterone Levels in Men with Male Hormone Levels = 250 ng/dL

THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc.® (NasdaqCM:RPRX) today reported it has submitted to the FDA a reanalysis of the previously completed 200 subject trial ZA-003 of Androxal® in the treatment of secondary hypogonadism as noted by Repros in the Company’s press release of November 9, 2010. The Company contracted an outside statistician, Tony Orlando, Ph.D., V.P., Global Data Division, Pharm-Olam International Ltd., to conduct the analysis.